Transgene Biotek Ltd.
BSE: TRABI · Healthcare Service Provider · sector
Key numbers
Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 31 companies in Healthcare Service Provider (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹0 cr vs borrowings ₹17 cr (FY26): borrowings are higher by ₹17 cr.
- Operating profit covered interest -0.5x in the last 12 months.
- Net loss in 6 of the last 6 quarters.
- No dividend in the last 5 financial years.
- Price ₹2.45 on 2026-10-26: -43.5% from the 52-week high, +33.9% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Quarterly results
| ₹ cr | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -1 | -0 | -0 | -0 | -0 | -0 |
| OPM % | -675.0% | -280.0% | -140.0% | -100.0% | -560.0% | -100.0% |
| Other income | 0 | 0 | 0 | 0 | 0 | 0 |
| Net profit | -1 | -0 | -0 | -0 | -0 | -0 |
| EPS (₹) | 0.09 | 0.06 | 0.05 | 0.05 | 0.06 | 0.05 |
| Revenue YoY | -37.5% | +20.0% | ||||
| Profit YoY | – | – |
Consolidated figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY21 | FY22 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -1 | -0 | -1 | -1 | -1 | -0 |
| Net profit | -10 | -10 | -1 | -1 | -2 | -2 |
| EPS (₹) | -1.38 | -1.37 | -0.09 | 0.09 | 0.22 | 0.21 |
| Revenue growth | -47.1% | +166.7% | +8.3% | -19.2% | – | |
| Profit growth | – | – | – | – | – | |
| Dividend / share (₹) | – | – | – | – | – |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | +32.9% | – | – |
| Net profit | – | – | – |
| EPS | – | – | – |
| Share price | – | -42.7% (2y) | -45.0% |
Balance sheet
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Shareholders' equity | 10 | 8 |
| Borrowings | 15 | 17 |
| Cash & equivalents | 0 | 0 |
| Total assets | 144 | 144 |
| Fixed assets | 3 | 3 |
| Capital work in progress | 0 | 0 |
| Investments | 0 | 0 |
| Receivables | 0 | 0 |
| Inventory | 0 | 0 |
| Payables | 2 | 0 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Cash from operations | 1 | -0 |
| Cash from investing | -2 | 0 |
| Cash from financing | 1 | -0 |
| Capex | 0 | 0 |
| Free cash flow | 1 | -0 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY25 | FY26 |
|---|---|---|
| ROE % | -6.7% | -19.7% |
| ROCE % | -1.8% | -2.3% |
| Debtor days | 12 | 15 |
| Inventory days | 48 | 59 |
| Payable days | 2,231 | 118 |
| Cash conversion cycle (days) | -2,171 | -44 |
| Working capital days | -16,064 | -21,135 |
Peers in Healthcare Service Provider
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| LALPATHLAB | ₹31,100 cr | 57.2x | 12.4x | 23.1% | 29.6% | 27.9% | +11.1% | 0.71% |
| VIJAYA | ₹14,362 cr | 76.6x | 15.0x | 21.4% | 30.1% | 42.2% | +21.0% | 0.14% |
| METROPOLIS | ₹10,989 cr | 54.5x | 7.3x | 14.2% | 19.7% | 24.2% | +12.8% | 0.19% |
| THYROCARE | ₹7,491 cr | 42.6x | 12.8x | 31.1% | 39.7% | 31.4% | +16.3% | 1.99% |
| NEPHROPLUS | ₹6,095 cr | 71.6x | 5.5x | 6.9% | 13.4% | 22.7% | – | – |
| SURAKSHA | ₹1,628 cr | 45.4x | 6.7x | 15.7% | 25.2% | 31.4% | – | – |
| KRSNAA | ₹1,617 cr | 16.6x | 1.6x | 10.5% | 11.1% | 26.8% | +16.6% | 0.55% |
| 3BBLACKBIO | ₹1,193 cr | 21.2x | 3.7x | 18.7% | 22.8% | 34.9% | +127.8% | 0.29% |
| HEALTHX | ₹857 cr | – | 3.2x | -0.5% | – | – | – | – |
| TRABI | ₹19 cr | 11.7x | 2.2x | -17.5% | -2.0% | -208.8% | +32.9% | – |
Documents
Links go to the original files on the exchange website.
About the company
| Sector | Healthcare |
| Industry | Healthcare Service Provider |
| Sub-industry | Healthcare Service Provider |
| Symbol | TRABI |
| BSE code | 526139 |
| ISIN | INE773D01018 |
| Face value | ₹10.0 |
| Incorporated | – |
| Website | – |
| Plants (India / abroad) | – |
Data built 2026-10-24 from BSE company filings (inline XBRL: Integrated Filing - Finance) + BSE results summary for earlier years; price = BSE close 2026-10-26.